Business Context and Reporting Period
This Form 6-K filing by DAQO NEW ENERGY CORP. is dated April 22, 2025, covering the month of April 2025. The report focuses on a material litigation update involving the company's subsidiary, Xinjiang Daqo New Energy Co., Ltd.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the specific litigation claim amounts.
Material Changes and Litigation Status
The filing details the progression of a contract dispute lawsuit filed against Xinjiang Daqo by Xinjiang Xian'an New Materials Co., Ltd. and its affiliate, Xinjiang Dengbo New Energy Co., Ltd.
- Initial Claim: Plaintiffs originally sought termination of a business agreement and compensation totaling RMB 1,958.5 million, later reduced to RMB 1,847.8 million.
- First Instance Verdict (July 2024): The court affirmed the termination of the agreement and ordered compensation of RMB 3.16 million for losses and attorney fees, rejecting claims for consequential damages.
- Second Instance Verdict (March 2025): The appellate court vacated the first instance decision and remanded the case for a new trial.
- Current Status (April 2025): Plaintiffs have further reduced their requested compensation to RMB 742.7 million. The final financial impact remains contingent upon the new trial's verdict.
Guidance, Outlook, and Risks
Management commentary is limited to the litigation update. The filing explicitly states that the litigation's impact on Xinjiang Daqo is contingent upon the final verdict. No forward-looking guidance regarding revenue, earnings, or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the current status of the remanded trial and any new court dates.
- Assess the potential financial exposure of the reduced RMB 742.7 million claim against the company's current liquidity.
- Review the company's most recent Form 20-F for baseline financial data not included in this 6-K.
- Monitor for further disclosures regarding the outcome of the new trial.